Patent US4433095A successfully refreshed from Google Patents.
Patent USRE33375E successfully refreshed from Google Patents.
USRE33375E
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatments employing drug-containing matrices for introduction into cellular lesion areas
Assignee: Matrix Pharmaceutical Inc
•
Filing: 1988-10-11
•
Granted: 1990-10-09
•
Expires: 2008-10-11
Abstract
Abstract Treatment of cellular disorders involving abnormal solid cellular growths involves introduction of cytotoxic reagents dispersed in a physiologically acceptable proteinaceous matrix into the solid cellular growth or area of an existing or removed solid cellular growth. Enhanced effectiveness of the drug is observed, with reduced cytotoxic effects on cells distant from the site of introduction. Other drugs may be included to enhance therapeutic gain and reduce adverse affects to normal tissue.
Inventors
- 👤 Edward E. Luck
- 👤 Dennis M. Brown
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:21
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/30; A61K47/42; A61L; A61L26/00; A61L26/0009; A61L26/0028; A61L26/0033; A61L26/0061; A61L26/0066; A61P; A61P35/00; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/602
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
54 words
A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug .Iadd.or proliferation inhibitor. .Iaddend.
Claim 2
Dependent Claim
54 words
A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug .Iadd.or proliferation inhibitor. .Iaddend.
Claim 3
Dependent Claim
17 words
A composition according to claim 1, wherein said cytotoxic drug is cis-platinum, adriamycin, bleomycin, 5-fluorouracil or vincristine.
Claim 4
Dependent Claim
14 words
A composition according to claim 1, having a vasoconstrictive amount of a vasoconstrictive drug.
Claim 5
Dependent Claim
14 words
A composition according to claim 3, wherein said vasoconstrictor drug is epinephrine or nor-epinephrine.
Claim 6
Independent Claim
91 words
A method for treating a neoplastic .Iadd.or hyperproliferative .Iaddend.lesion or surrounding tissue which comprises: introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement, consisting essentially .[.or.]. .Iadd.of a .Iaddend.physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass including at least one cytotoxic drug .Iadd.or proliferation inhibitor .Iaddend.uniformly dispersed in said composition.[.;.]..Iadd.:.Iaddend. whereby said drug is slowly released into the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction.
Claim 7
Independent Claim
91 words
A method for treating a neoplastic .Iadd.or hyperproliferative .Iaddend.lesion or surrounding tissue which comprises: introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement, consisting essentially .[.or.]. .Iadd.of a .Iaddend.physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass including at least one cytotoxic drug .Iadd.or proliferation inhibitor .Iaddend.uniformly dispersed in said composition.[.;.]..Iadd.:.Iaddend. whereby said drug is slowly released into the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction.
Claim 8
Dependent Claim
15 words
A method according to claim 5, wherein said proteinaceous composition is a collagen fibril dispersion.
Claim 9
Dependent Claim
21 words
A method according to claim 6, wherein said drug is at least one of cis-platinum, adriamycin, 5fluorouracil, bleomycin, vincristine, or methotrexate.
Claim 10
Dependent Claim
25 words
A method according to claim 7, wherein said composition includes a sufficient amount of a vasoconstrictor to constrict capillaries in the vicinity of said lesion.
Claim 11
Dependent Claim
13 words
A method according to claim 8, wherein said vasoconstrictor is epinephrine or nor-epinephrine.
Claim 12
Dependent Claim
11 words
A method according to claim 7, wherein said drug is cis-platinum.
Claim 13
Dependent Claim
11 words
A method according to claim 7, wherein said drug is 5-fluorouracil.
Claim 14
Dependent Claim
20 words
A method according to claim 5, comprising the additional step of treating said lesion size with radiation or heat. .Iadd.
Claim 15
Dependent Claim
97 words
A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug. .Iaddend. .Iadd.14. A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or
Claim 16
Dependent Claim
97 words
A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or fibrinogen of a cytotoxic drug. .Iaddend. .Iadd.14. A proteinaceous composition comprising from 30% to 95% of collagen and/or fibrinogen dispersed in an aqueous medium as an amorphous flowable mass at a concentration of from about 5 to 75 mg/ml and from about 0.1 to 50 weight percent based on said collagen and/or
Claim 17
Dependent Claim
186 words
fibrinogen of a proliferation inhibitor. .Iaddend. .Iadd.15. A method for treating a neoplastic lesion or surrounding tissue which comprises: introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement consisting essentially of a physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass, including at least one cytotoxic drug or proliferation inhibitor uniformly dispersed in said composition; whereby said drug is slowly released into the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction. .Iaddend. .Iadd.16. A method for treating a hyperproliferative lesion or surrounding tissue which comprises: introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement consisting essentially of a physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass, including at least one cytotoxic drug or proliferation inhibitor uniformly dispersed in said composition; whereby said drug is slowly released into the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction. .Iaddend.
Claim 18
Dependent Claim
186 words
fibrinogen of a proliferation inhibitor. .Iaddend. .Iadd.15. A method for treating a neoplastic lesion or surrounding tissue which comprises: introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement consisting essentially of a physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass, including at least one cytotoxic drug or proliferation inhibitor uniformly dispersed in said composition; whereby said drug is slowly released into the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction. .Iaddend. .Iadd.16. A method for treating a hyperproliferative lesion or surrounding tissue which comprises: introducing at the site of said lesion a proteinaceous matrix composition capable of stable placement consisting essentially of a physiologically acceptable matrix forming collagen, fibrinogen or combination thereof, dispersed in an aqueous medium as an amorphous flowable mass, including at least one cytotoxic drug or proliferation inhibitor uniformly dispersed in said composition; whereby said drug is slowly released into the immediate environment avoiding significant levels of the drug at sites distant from the site of introduction. .Iaddend.
References Cited (Backward Citations)
US2589210A
Cited
US4177263A
Cited
US4391797A
Cited
US4347234A
Cited
US4322398A
Cited
US4230687A
Cited
US4407787A
Cited
US4349530A
Cited
EP0083868A1
Cited
US4424208A
Cited
EP0086627A1
Cited
US4536387A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-10-08 | 1994-04-09 | 1994-10-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-10-08 | 1998-04-09 | 1998-10-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-10-08 | 2002-04-09 | 2002-10-09 | $7700.00 | Window Closed / Lapsed |